Should We Rename DCIS?

Ductal carcinoma in situ was all over the news this week, after the Journal of the American Medical Association published “Overdiagnosis and Overtreatment in Cancer, An Opportunity for Improvement.” This is a good, and necessary, conversation. DCIS was front and center as one of the prime candidates for overtreatment, and the panel proposed renaming it . . . → Read More: Should We Rename DCIS?

What’s In A Name? Cancer – or Indolent Lesions of Epithelial Origin

“What’s In A Name? Cancer – or Indolent Lesions of Epithelial Origin.” By Jody Schoger, Michael S. Cowher, M.D., and Deanna J. Attai, M.D., F.A.C.S., BCSMCommunity.org.

What’s in a name? In the case of cancer, there are myths, fears and misinformation – more than perhaps any other illness. Cancer encompasses hundreds of different diseases and . . . → Read More: What’s In A Name? Cancer – or Indolent Lesions of Epithelial Origin

“Carcinoma”: What’s in a name?

As part of a National Cancer Institute working group, Dr. Laura J. Esserman MD, MBA of Mt Zion Carol Franc Buck Breast Cancer Center along with colleagues Ian Thompson MD of the University of Texas Health Science Center at San Antonio and Brian Reid MD, PhD of Fred Hutchinson Cancer Research Center in Seattle, Washington, . . . → Read More: “Carcinoma”: What’s in a name?

Breast Screening Costs High for Seniors

“Breast Screening Costs High for Seniors.” By Nancy Walsh, MedPage today

Costs associated with screening for breast cancer among older women remain high, with considerable geographic variation as well as some potentially undesirable implications for diagnosis, a retrospective study found. The annual cost to Medicare for breast cancer screening among women 66 and older was . . . → Read More: Breast Screening Costs High for Seniors